Aspartic proteases in drug discovery.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Current pharmaceutical design

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/138161207779313560PMID 17313361
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ritonavir

  2012cited by this paper
• Integrins in drug targeting-RGD templates in toxins.

  2006cited by this paper
• Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor.

  2006cited by this paper
• Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients

  2005cited by this paper
• Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.

  2005cited by this paper
• Catalytically inactive human cathepsin D triggers fibroblast invasive growth

  2005cited by this paper
• Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics.

  2005cited by this paper
• Presenilin function and γ‐secretase activity

  2005cited by this paper
• Cyclic sulfamide gamma-secretase inhibitors.

  2005cited by this paper
• Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.

  2005cited by this paper
• The discovery and preparation of disubstituted novel amino-aryl-piperidine-based renin inhibitors.

  2005cited by this paper
• Discovery of novel non-peptidic ketopiperazine-based renin inhibitors.

  2005cited by this paper
• Progress in the discovery of BACE inhibitors.

  2005cited by this paper
• A Nine-transmembrane Domain Topology for Presenilin 1*

  2005cited by this paper
• Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors

  2005cited by this paper
• A role for cathepsin E in the processing of mast-cell carboxypeptidase A

  2005cited by this paper
• Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.

  2005cited by this paper
• Prospects for the resistance to HIV protease inhibitors: current drug design approaches and perspectives.

  2005cited by this paper
• The Expression and Function of Cathepsin E in Dendritic Cells1

  2005cited by this paper
• Down syndrome, Alzheimer's disease and seizures.

  2005cited by this paper
• gamma-Secretase as a target for drug intervention in Alzheimer's disease.

  2004cited by this paper
• Role of enzymatically inactive procathepsin D in lung cancer.

  2004cited by this paper
• Increasing number of anti-HIV drugs but no definite cure Review of anti-HIV drugs

  2004cited by this paper
• Identification of a New Presenilin-dependent ζ-Cleavage Site within the Transmembrane Domain of Amyloid Precursor Protein*♦

  2004cited by this paper
• Fosamprenavir: advancing HIV protease inhibitor treatment options

  2004cited by this paper
• Rational design and synthesis of selective BACE-1 inhibitors.

  2004cited by this paper
• Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.

  2004cited by this paper
• Notch regulation of lymphocyte development and function

  2004cited by this paper
• Consensus Analysis of Signal Peptide Peptidase and Homologous Human Aspartic Proteases Reveals Opposite Topology of Catalytic Domains Compared with Presenilins*

  2004cited by this paper
• Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases.

  2004cited by this paper
• Crystal structure of an activation intermediate of cathepsin E.

  2004cited by this paper
• Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs.

  2004cited by this paper
• Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.

  2004cited by this paper
• Design and development of BACE-1 inhibitors.

  2004cited by this paper
• Processing of Pulmonary Surfactant Protein B by Napsin and Cathepsin H*

  2004cited by this paper
• Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1).

  2004cited by this paper
• Apo and inhibitor complex structures of BACE (beta-secretase).

  2004cited by this paper
• In vivo inhibition of Aβ production by memapsin 2 (β‐secretase) inhibitors

  2004cited by this paper
• On the mechanism of SPP‐catalysed intramembrane proteolysis; conformational control of peptide bond hydrolysis in the plane of the membrane

  2004cited by this paper
• New inhibitors of the malaria aspartyl proteases plasmepsin I and II.

  2003cited by this paper
• Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents.

  2003cited by this paper
• High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II.

  2003cited by this paper
• Involvement of Napsin A in the C- and N-terminal Processing of Surfactant Protein B in Type-II Pneumocytes of the Human Lung*

  2003cited by this paper
• Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors.

  2003cited by this paper
• Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides.

  2003cited by this paper
• Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangement.

  2003cited by this paper
• Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration.

  2003cited by this paper
• Aspartic Peptidase Inhibitors: Implications in Drug Development

  2003cited by this paper
• Adipsin, a Biomarker of Gastrointestinal Toxicity Mediated by a Functional γ-Secretase Inhibitor*

  2003cited by this paper
• Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma.

  2003cited by this paper
• BACE1 and BACE2 in pathologic and normal human muscle.

  2003cited by this paper
• C2-symmetric inhibitors of Plasmodium falciparum plasmepsin II: synthesis and theoretical predictions.

  2003cited by this paper
• New potent C2-symmetric malaria plasmepsin I and II inhibitors.

  2003cited by this paper
• Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex.

  2003cited by this paper
• Association of cathepsin E deficiency with development of atopic dermatitis.

  2003cited by this paper
• Intramembrane-cleaving aspartic proteases and disease: presenilins, signal peptide peptidase and their homologs.

  2003cited by this paper
• Structure-based design of aliskiren, a novel orally effective renin inhibitor.

  2003cited by this paper
• Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes.

  2003cited by this paper
• Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells.

  2003cited by this paper
• Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma

  2003cited by this paper
• Recent advances in the development of gamma-secretase inhibitors.

  2002cited by this paper
• Identification of a novel family of presenilin homologues.

  2002cited by this paper
• Structure and mechanism of the pepsin-like family of aspartic peptidases.

  2002cited by this paper
• Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells

  2002cited by this paper
• Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1.

  2002cited by this paper
• Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets

  2002cited by this paper
• Novel Class of Polytopic Proteins with Domains Associated with Putative Protease Activity

  2002cited by this paper
• Pronapsin A and B gene expression in normal and malignant human lung and mononuclear blood cells.

  2002cited by this paper
• Aspartic proteinases in disease: a structural perspective.

  2002cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Design of substrate-based inhibitors of human beta-secretase.

  2002cited by this paper
• Identification of Signal Peptide Peptidase, a Presenilin-Type Aspartic Protease

  2002cited by this paper
• Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3.

  2002cited by this paper
• Follow the protons: a low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases.

  2001cited by this paper
• BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.

  2001cited by this paper
• Analysis of crystal structures of aspartic proteinases: On the role of amino acid residues adjacent to the catalytic site of pepsin‐like enzymes

  2001cited by this paper
• Piperidine renin inhibitors: from leads to drug candidates.

  2001cited by this paper
• Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch.

  2001cited by this paper
• Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase).

  2001cited by this paper
• Intramembrane Proteolysis of Signal Peptides: An Essential Step in the Generation of HLA-E Epitopes1

  2001cited by this paper
• A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells

  2001cited by this paper
• ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site.

  2000cited by this paper
• Expression Analysis of BACE2 in Brain and Peripheral Tissues*

  2000cited by this paper
• Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor.

  2000cited by this paper
• BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents

  2000cited by this paper
• Identification of a novel aspartic-like protease differentially expressed in human breast cancer cell lines.

  2000cited by this paper
• Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

  2000cited by this paper
• Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase).

  2000cited by this paper
• The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the Down critical region

  2000cited by this paper
• Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1.

  2000cited by this paper
• Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin.

  2000cited by this paper
• L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity.

  2000cited by this paper
• In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632

  2000cited by this paper
• Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases

  2000cited by this paper
• Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans.

  2000cited by this paper
• Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity

  1999cited by this paper
• Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II.

  1999cited by this paper
• Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

  1999cited by this paper
• Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?

  1999cited by this paper
• Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas

  1999cited by this paper

• Physico-Chemical Insights into the Catalytic Inhibition of Plasmodium falciparum Plasmepsin II Activity by Repurposing Fluoroquinolone Drugs.

  2026cites this paper
• Targeting a Glutamic Acid in PDEδ with Fluoromethyl-Aryl Electrophiles Impairs K‑Ras Signaling

  2026cites this paper
• Proteome-Wide Covalent Targeting of Acidic Residues with Tunable N-Aryl Aziridines.

  2025cites this paper
• Imidazolidine‐Based Aspartate Inhibitors for Candida Infections

  2025cites this paper
• Targeting Cathepsins in Neurodegeneration: Biochemical Advances

  2025cites this paper
• Rational Enzyme Evolution by Facilitating Correlated Motion along the Reaction.

  2025cites this paper
• First Insight into the Degradome of Aspergillus ochraceus: Novel Secreted Peptidases and Their Inhibitors

  2024cites this paper
• Screening, Growing, and Validation by Catalog: Using Synthetic Intermediates from Natural Product Libraries to Discover Fragments for an Aspartic Protease Through Crystallography

  2024cites this paper
• Compilation of secondary metabolites produced by fungal strains identified as Aspergillus flavus var. oryzae (formerly Aspergillus oryzae), with a review of biotechnological applications, and computational studies of their anti-COVID-19 activity

  2024cites this paper
• Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia

  2023cites this paper
• Transcriptomic analysis reveals responses to a polluted sediment in the Mediterranean copepod Acartia clausi.

  2023cites this paper
• Predicted cellular interactors of the endogenous retrovirus-K protease enzyme

  2022cites this paper
• Exploring Aspartic Protease Inhibitor Binding to Design Selective Antimalarials

  2022cites this paper
• Plant Metabolites as Antiviral Preparations Against Coronaviruses

  2021cites this paper
• An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease

  2021cites this paper
• Science's Response to CoVID‐19

  2021cites this paper
• Plasmepsin Inhibitors in Antimalarial Drug Discovery: Medicinal Chemistry and Target Validation (2000 - Present).

  2020cites this paper
• Inhibitors of HIV protease in cancer therapy

  2020cites this paper
• Identification of the natural compound inhibitors against Plasmodium falciparum plasmepsin-II via common feature based screening and molecular dynamics simulations

  2020cites this paper
• Ligand retargeting by binding site analogy.

  2019cites this paper
• Current progress in antimalarial pharmacotherapy and multi-target drug discovery.

  2019cites this paper
• Discovery of Orally Active Hydroxyethylamine Based SPPL2a Inhibitors.

  2019cites this paper
• Exploiting Structural Dynamics To Design Open-Flap Inhibitors of Malarial Aspartic Proteases.

  2019cites this paper
• The Aspartic Protease Ddi1 Contributes to DNA-Protein Crosslink Repair in Yeast

  2019cites this paper
• Factors Influencing the Potency of Alzheimer Inhibitors: Computational and Docking Studies

  2018cites this paper
• Reviewing Mechanistic Peptidomics in Body Fluids Focusing on Proteases

  2018cites this paper
• Enzymatic Transition States and Drug Design.

  2018cites this paper
• Asymmetric peptidomimetics containing L-tartaric acid core inhibit the aspartyl peptidase activity and growth of Leishmania amazonensis promastigotes

  2018cites this paper
• β‐Secretase (BACE1) Inhibitors from Natural Products

  2017cites this paper
• 8.09 – Verubecestat

  2017cites this paper
• Plasmodium berghei plasmepsin VIII is essential for sporozoite gliding motility.

  2017cites this paper
• Proteolytic Cleavage-Mechanisms, Function, and "Omic" Approaches for a Near-Ubiquitous Posttranslational Modification.

  2017cites this paper
• XModeScore: a novel method for accurate protonation/tautomer-state determination using quantum-mechanically driven macromolecular X-ray crystallographic refinement

  2016cites this paper
• Large‐scale Structure‐based Prediction and Identification of Novel Protease Substrates using Computational Protein Design

  2016cites this paper
• An Integrated Approach for Fragment‐Based Lead Discovery: Virtual, NMR, and High‐Throughput Screening Combined with Structure‐Guided Design. Application to the Aspartyl Protease Renin.

  2016cites this paper
• iBodies: Modular Synthetic Antibody Mimetics Based on Hydrophilic Polymers Decorated with Functional Moieties

  2016cites this paper
• The binding of small carbazole derivative (P7C3) to protofibrils of the Alzheimer’s disease and β-secretase: Molecular dynamics simulation studies

  2015cites this paper
• Aspartic protease inhibitors containing tertiary alcohol transition-state mimics.

  2015cites this paper
• Frontiers in Clinical Drug Research - Alzheimer Disorders

  2015cites this paper
• Protease inhibitors from marine organisms

  2015cites this paper
• Design, synthesis and biological evaluation of tasiamide B derivatives as BACE1 inhibitors.

  2015cites this paper
• Fighting malaria: structure-guided discovery of nonpeptidomimetic plasmepsin inhibitors.

  2015cites this paper
• An Automated High-Throughput Cell-Based Multiplexed Flow Cytometry Assay to Identify Novel Compounds to Target Candida albicans Virulence-Related Proteins

  2014cites this paper
• Silicon Mimics of Unstable Carbon

  2014cites this paper
• Reaction Mechanism of Human Renin Studied by Quantum Mechanics/Molecular Mechanics (QM/MM) Calculations

  2014cites this paper
• Decoding the Anti-Trypanosoma cruzi Action of HIV Peptidase Inhibitors Using Epimastigotes as a Model

  2014cites this paper
• Transition state mimetics of the Plasmodium export element are potent inhibitors of Plasmepsin V from P. falciparum and P. vivax.

  2014cites this paper
• Structure-based β-secretase (BACE1) inhibitors.

  2014cites this paper
• Molecular dynamics studies on both bound and unbound renin protease

  2014cites this paper
• Investigation of a link between raised levels of pepsinogen in blood as a mediator of in-vitro clot lysis in acid and a cause of abnormal factor XIII screening tests

  2014cites this paper
• Aspartic Proteolytic Inhibitors Induce Cellular and Biochemical Alterations in Fungal Cells

  2013cites this paper
• Elucidating the catalytic mechanism of human renin with hybrid quantum mechanics and molecular m echanics studies

  2013cites this paper
• Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease.

  2013cites this paper
• Drug Design

  2013cites this paper
• Applications of asymmetric organocatalysis in medicinal chemistry.

  2013cites this paper
• B cell survival, surface BCR and BAFFR expression, CD74 metabolism, and CD8− dendritic cells require the intramembrane endopeptidase SPPL2A

  2013influential citation
• Discovery of biphenylacetamide-derived inhibitors of BACE1 using de novo structure-based molecular design.

  2013cites this paper
• Transition State Analogues of Enzymatic Reaction as Potential Drugs

  2013cites this paper
• Understanding HIV-1 protease autoprocessing for novel therapeutic development.

  2013cites this paper
• Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease

  2013cites this paper
• ASSAY TECHNOLOGIES FOR PROTEASES

  2013cites this paper
• Protein Interaction Studies with Low Molecular Weight Ligands : Applications for Drug Discovery, Basic Research and Diagnostic Tool Design

  2013cites this paper
• Expression and purification of the predicted PEG10 aspartyl protease domain

  2013cites this paper
• EXTRACTION OF CYSTATIN (ENZYME INHIBITORS) FROM ANIMAL SLAUGHTERHOUSE WASTES

  2013cites this paper
• Progress in the field of aspartic proteinases in cheese manufacturing: structures, functions, catalytic mechanism, inhibition, and engineering

  2013cites this paper
• Allosteric inhibition of BACE1 by an exosite-binding antibody.

  2013cites this paper
• Search for cancer treatment continues : Procathepsin

  2012cites this paper
• Boron containing compounds as protease inhibitors.

  2012cites this paper
• Search for cancer treatment continues: Procathepsin D

  2012cites this paper
• Isolation, affinity purification and biochemical characterization of a lysosomal cathepsin D from the deuterostome Asterias rubens.

  2012cites this paper
• Conformational Dynamics of HIV-1 protease: a Comparative molecular Dynamics Simulation Study with Multiple AMBER Force Fields

  2012cites this paper
• New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.

  2012cites this paper
• Mechanistic Insights into the Inhibition of Endo-β 1,4 Xyloglucan Hydrolase by a Classical Aspartic Protease Inhibitor

  2012cites this paper
• Multiple effects of pepstatin A on Trypanosoma cruzi epimastigote forms

  2012cites this paper
• Facile and rapid route for the synthesis of novel norstatine analogs via PADAM-cyclization methodology

  2012cites this paper
• Recent advances in plasmepsin medicinal chemistry and implications for future antimalarial drug discovery efforts.

  2012cites this paper
• Serine protease inhibition by a silanediol peptidomimetic.

  2012cites this paper
• Facile and rapid route for the synthesis of novel conformationally constrained norstatine analogs via PADAM-cyclization methodology.

  2012cites this paper
• Flexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulations.

  2012cites this paper
• Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design.

  2012cites this paper
• Protease Inhibitors: Emphasizing Functional Aspects of Aspartic Protease Inhibitors

  2012cites this paper
• The catalytic mechanism of mouse renin studied with QM/MM calculations.

  2012cites this paper
• Schistosoma Mansonii aspartic protease expression and refolding trials

  2011cites this paper
• Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions

  2011cites this paper
• Looking at the proteases from a simple perspective

  2011cites this paper
• Carbazole-containing arylcarboxamides as BACE1 inhibitors.

  2011cites this paper
• Binding to the open conformation of HIV‐1 protease

  2011cites this paper
• The Plasmepsin Family as Antimalarial Drug Targets

  2011cites this paper
• Characterisation of aspartic protease activity from the scabies mite Sarcoptes scabiei

  2011cites this paper
• Evolution of Diverse Classes of Renin Inhibitors through the Years

  2011cites this paper
• Aspartic Proteases of Human Pathogenic Fungi are Prospective Targets for the Generation of Novel and Effective Antifungal Inhibitors

  2011cites this paper
• Synthesis and structural study of ethylmethylsilanediol by quantum chemical calculations and IR and Raman spectroscopies

  2011cites this paper
• Fluorescence lifetime assays: current advances and applications in drug discovery

  2011cites this paper
• Design and synthesis of potent and selective BACE-1 inhibitors.

  2010cites this paper
• Procathepsin D and cancer: From molecular biology to clinical applications.

  2010cites this paper
• Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core.

  2010cites this paper
• Fragment-based discovery and optimization of BACE1 inhibitors.

  2010cites this paper
• Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors

  2010cites this paper
• Cystatin Superfamily

  2010cites this paper
• Mammalian and viral protease inhibitors

  2010cites this paper